<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02468583</url>
  </required_header>
  <id_info>
    <org_study_id>FX006-2014-007</org_study_id>
    <nct_id>NCT02468583</nct_id>
  </id_info>
  <brief_title>Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee</brief_title>
  <official_title>A Double-Blind, Randomized, Parallel Group, Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Flexion Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Flexion Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was a double-blind, randomized, parallel group, proof of concept study comparing
      FX006 to Kenalog®-40 (triamcinolone acetonide injectable suspension, USP) in patients with
      post-traumatic osteoarthritis of the knee.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was a double-blind, randomized, parallel group, proof of concept study patients
      with post-traumatic osteoarthritis (PTOA) of the knee. Approximately 124 eligible patients
      were intended to be randomized to one of the two treatment groups (1:1) and treated with a
      single intra-articular (IA) injection of:

        -  32 mg of FX006

        -  40 mg of Kenalog®-40 (triamcinolone acetonide injectable suspension, USP)

      Each prospective patient underwent a screening evaluation to confirm a diagnosis of PTOA of
      the knee and concurrence with all other eligibility criteria. Patients were be treated on Day
      1 (Baseline) and returned to the clinic at Weeks 4, 8 and 12 for evaluation of safety and
      efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Change From Baseline in the Weekly Mean of the Average Daily (24-hour) Pain Intensity Scores Over Weeks 5 to 10</measure>
    <time_frame>5-10 Weeks</time_frame>
    <description>The pain intensity score is measured using an 11-point numeric rating scale (NRS), where 0 indicates &quot;no pain&quot; and 10 indicates &quot;pain as bad as you can imagine.&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weekly Mean of the Average Daily (24-hr) Pain Intensity Scores, Change From Baseline to Each Week and Average Change From Baseline Over Weeks 1 to 12 and Weeks 4 to 12</measure>
    <time_frame>12 Weeks</time_frame>
    <description>The pain intensity score is measured using an 11-point numeric rating scale (NRS), where 0 indicates &quot;no pain&quot; and 10 indicates &quot;pain as bad as you can imagine.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Experiencing a &gt;20% Decrease in Pain From Baseline in Weekly Mean of the Average Daily (24-hr) Pain Intensity Scores at Each Week</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Experiencing a &gt;50% or &gt;30% Decrease in Pain From Baseline in Weekly Mean of Average Daily 24-hr Pain Intensity Scores at Each Week</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Experiencing Each of &gt;50% or &gt;30% Decrease in Pain From Baseline in Weekly Mean of the Average Daily (24-hr) Pain Intensity Scores at Each Week</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC A (Pain Subscale)</measure>
    <time_frame>12 weeks</time_frame>
    <description>change from Baseline to Weeks 4, 8 and 12 average change from Baseline over Weeks 4 to 8 and Weeks 4 to 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC A1 (Pain on Walking Question)</measure>
    <time_frame>12 weeks</time_frame>
    <description>change from Baseline to Weeks 4, 8 and 12 average change from Baseline over Weeks 4 to 8 and Weeks 4 to 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC B (Stiffness)</measure>
    <time_frame>12 weeks</time_frame>
    <description>change from Baseline to Weeks 4, 8 and 12 average change from Baseline over Weeks 4 to 8 and Weeks 4 to 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC C (Function)</measure>
    <time_frame>12 weeks</time_frame>
    <description>change from Baseline to Weeks 4, 8 and 12 average change from Baseline over Weeks 4 to 8 and Weeks 4 to 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC (Total):</measure>
    <time_frame>12 weeks</time_frame>
    <description>change from Baseline to Weeks 4, 8 and 12 average change from Baseline over Weeks 4 to 8 and Weeks 4 to 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee Injury and Osteoarthritis Score (KOOS)</measure>
    <time_frame>12 weeks</time_frame>
    <description>change from Baseline to Weeks 4, 8 and 12 average change from Baseline over Weeks 4 to 8 and Weeks 4 to 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC) at Weeks 4, 8 and 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Change (CGIC) at Weeks 4, 8 and 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Responders (Defined as Patients With High Improvement in Pain or Function) According to OMERACT-OARSI Criteria at Weeks 4, 8 and 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Pain Relief</measure>
    <time_frame>Baseline to &gt;30% improvement</time_frame>
    <description>Time to onset of pain relief in days is defined as the time from first dose to the first daily pain assessment showing &gt;30% improvement from the weekly mean of the average daily (24-hr) pain intensity scores at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Weekly and Total Consumption of Rescue Medication</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Post-traumatic Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>FX006 32mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 5 mL intra-articular (IA) injection Extended-release formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TCA IR 40 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single 1 mL intra-articular (IA) injection Immediate-release formulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FX006 32 mg</intervention_name>
    <description>Experimental</description>
    <arm_group_label>FX006 32mg</arm_group_label>
    <other_name>Zilretta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TCA IR 40 mg</intervention_name>
    <description>Comparator</description>
    <arm_group_label>TCA IR 40 mg</arm_group_label>
    <other_name>Kenalog®-40</other_name>
    <other_name>Triamcinolone Acetonide Crystalline Suspension (TAcs)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willingness and ability to comply with the study procedures and visit schedules and
             ability to follow verbal and written instructions

          -  Male or female ≥20 and ≤50 years of age

          -  Diagnosis of post-traumatic OA of the knee

          -  Kellgren-Lawrence (K-L) Grade 2 or 3 in the index knee within 6 months prior to or at
             Screening

          -  Qualifying mean score on the 24-h average pain score (0-10 numeric rating scale)

          -  Body mass index (BMI) ≤ 40 kg/m2

          -  Willingness to abstain from use of restricted medications and therapies during the
             study

        Exclusion Criteria:

          -  Prior osteotomy of the index knee

          -  Any condition that could possibly confound the patient's assessment of index knee pain
             in the judgement of the Investigator (i.e., ipsilateral hip OA, gout, radicular low
             back pain and hip pain that is referred to the knee that could cause misclassifcation,
             pain in any other area of the lower extremeties or back that is equal to or greater
             than the index knee pain)

          -  Fibromyalgia, Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing
             spondylitis, arthritis associated with inflammatory bowel disease

          -  History of, or clinical signs and symptoms of active infection of the index knee

          -  Crystal disease of the index knee within one month of Screening

          -  Disease secondary to surgical treatment of Shatzker grade IV, V, or VI tibial plateau
             fractures (OTA classification C2 or C3); surgical treatment of OTA calssifcation C2 or
             C3 distal femur fractures; or &gt;2mm of articular incongruity after surgery

          -  IA corticosteroid (investigational or marketed) in any joint within 3 months of
             Screening

          -  IA hyaluronic acid (investigational or marketed) in the index knee within 6 months of
             Screening

          -  Intramuscular (IM) or oral corticosteroids (investigational or marketed) within 1
             month of Screening

          -  Any other IA investigational drug/biologic within 6 months of Screening

          -  Prior use of FX006

          -  Prior arthroplasty of any type of the index knee or planned/anticipated surgery of the
             index knee during the study period

          -  Type 1 or Type 2 diabetes requiring insulin

          -  Women of child-bearing potential not using effective contraception or who are pregnant
             or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Bodick, MD</last_name>
    <role>Study Director</role>
    <affiliation>Flexion Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Antonio Military Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2015</study_first_submitted>
  <study_first_submitted_qc>June 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2015</study_first_posted>
  <results_first_submitted>November 6, 2017</results_first_submitted>
  <results_first_submitted_qc>December 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 21, 2017</results_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Post-traumatic</keyword>
  <keyword>Knee</keyword>
  <keyword>Pain</keyword>
  <keyword>Corticosteroid</keyword>
  <keyword>Intra-articular</keyword>
  <keyword>Injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>FX006 32 mg</title>
          <description>3 subjects received FX006 32 mg as a single 5 mL IA injection</description>
        </group>
        <group group_id="P2">
          <title>TCA IR 40 mg</title>
          <description>3 subjects received TCA IR 40 mg as a single 1 mL IA injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FX006 32 mg</title>
          <description>FX006: Single 5 mL IA injection</description>
        </group>
        <group group_id="B2">
          <title>TCA IR 40 mg</title>
          <description>TCA IR: Single 1 mL IA injection</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" lower_limit="36" upper_limit="49"/>
                    <measurement group_id="B2" value="40" lower_limit="37" upper_limit="47"/>
                    <measurement group_id="B3" value="42" lower_limit="36" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Change From Baseline in the Weekly Mean of the Average Daily (24-hour) Pain Intensity Scores Over Weeks 5 to 10</title>
        <description>The pain intensity score is measured using an 11-point numeric rating scale (NRS), where 0 indicates &quot;no pain&quot; and 10 indicates &quot;pain as bad as you can imagine.&quot;</description>
        <time_frame>5-10 Weeks</time_frame>
        <population>Given that the study was closed early, with only 5% of the planned study population enrolled, efficacy data were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FX006 32 mg</title>
            <description>FX006: Single 5 mL IA injection</description>
          </group>
          <group group_id="O2">
            <title>TCA IR 40 mg</title>
            <description>TCA IR: Single 1 mL IA injection</description>
          </group>
        </group_list>
        <measure>
          <title>Average Change From Baseline in the Weekly Mean of the Average Daily (24-hour) Pain Intensity Scores Over Weeks 5 to 10</title>
          <description>The pain intensity score is measured using an 11-point numeric rating scale (NRS), where 0 indicates &quot;no pain&quot; and 10 indicates &quot;pain as bad as you can imagine.&quot;</description>
          <population>Given that the study was closed early, with only 5% of the planned study population enrolled, efficacy data were not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Mean of the Average Daily (24-hr) Pain Intensity Scores, Change From Baseline to Each Week and Average Change From Baseline Over Weeks 1 to 12 and Weeks 4 to 12</title>
        <description>The pain intensity score is measured using an 11-point numeric rating scale (NRS), where 0 indicates &quot;no pain&quot; and 10 indicates &quot;pain as bad as you can imagine.&quot;</description>
        <time_frame>12 Weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Experiencing a &gt;20% Decrease in Pain From Baseline in Weekly Mean of the Average Daily (24-hr) Pain Intensity Scores at Each Week</title>
        <time_frame>12 Weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Experiencing a &gt;50% or &gt;30% Decrease in Pain From Baseline in Weekly Mean of Average Daily 24-hr Pain Intensity Scores at Each Week</title>
        <time_frame>12 Weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Experiencing Each of &gt;50% or &gt;30% Decrease in Pain From Baseline in Weekly Mean of the Average Daily (24-hr) Pain Intensity Scores at Each Week</title>
        <time_frame>12 Weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WOMAC A (Pain Subscale)</title>
        <description>change from Baseline to Weeks 4, 8 and 12 average change from Baseline over Weeks 4 to 8 and Weeks 4 to 12</description>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WOMAC A1 (Pain on Walking Question)</title>
        <description>change from Baseline to Weeks 4, 8 and 12 average change from Baseline over Weeks 4 to 8 and Weeks 4 to 12</description>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WOMAC B (Stiffness)</title>
        <description>change from Baseline to Weeks 4, 8 and 12 average change from Baseline over Weeks 4 to 8 and Weeks 4 to 12</description>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WOMAC C (Function)</title>
        <description>change from Baseline to Weeks 4, 8 and 12 average change from Baseline over Weeks 4 to 8 and Weeks 4 to 12</description>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WOMAC (Total):</title>
        <description>change from Baseline to Weeks 4, 8 and 12 average change from Baseline over Weeks 4 to 8 and Weeks 4 to 12</description>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Knee Injury and Osteoarthritis Score (KOOS)</title>
        <description>change from Baseline to Weeks 4, 8 and 12 average change from Baseline over Weeks 4 to 8 and Weeks 4 to 12</description>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression of Change (PGIC) at Weeks 4, 8 and 12</title>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression of Change (CGIC) at Weeks 4, 8 and 12</title>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Responders (Defined as Patients With High Improvement in Pain or Function) According to OMERACT-OARSI Criteria at Weeks 4, 8 and 12</title>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Pain Relief</title>
        <description>Time to onset of pain relief in days is defined as the time from first dose to the first daily pain assessment showing &gt;30% improvement from the weekly mean of the average daily (24-hr) pain intensity scores at Baseline</description>
        <time_frame>Baseline to &gt;30% improvement</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Weekly and Total Consumption of Rescue Medication</title>
        <time_frame>12 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected following IA administration through the final study visit at week 12.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>FX006 32 mg</title>
          <description>FX006: Single 5 mL IA injection</description>
        </group>
        <group group_id="E2">
          <title>TCA IR 40 mg</title>
          <description>TCA IR: Single 3 mL IA injection</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tooth Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was terminated early with only 5% of the planned study population enrolled, efficacy data were not analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Scott Kelley, VP of Medical Affairs</name_or_title>
      <organization>Flexion Therapeutics</organization>
      <phone>781-305-7142</phone>
      <email>skelley@flexiontherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

